在多发性硬化症中接受干扰素β-1a或干扰素β-1a治疗的老年多发性硬化症患者的结局MS PATHS
Le H Hua1, Carrie M Hersh1, Lana Zhovtis Ryerson2
1Department of Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Neurodegenerative disease management
|July 15, 2025
概括
多发性硬化症 (MS) 越来越多地被诊断为老年人. 现实数据显示,在老年多发性硬化症患者中,干扰素β-1a治疗在24个月内保持了低复发率和稳定的残疾.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 现实世界的证据研究研究.
背景情况:
- 多发性硬化症 (MS) 的患病率在老年人群中正在增加.
- 这项研究研究了老年 (≥60岁) 和年轻的多发性硬化症患者的结局.
- 将干扰素β-1a治疗与无疾病修饰疗法 (无DMT) 进行比较.
研究的目的:
- 描述和比较老年和年轻多发性硬化症患者的治疗结果.
- 评估干扰素β-1a在患有多发性硬化症的老年人中的疗效.
- 评估不同年龄组和治疗队列的残疾进展和复发率.
主要方法:
- 利用了767名接受干扰素治疗和2783名不接受DMT治疗的患者的现实数据.
- 在24个月的时间内评估结果.
- 测量了年度复发率 (ARR),患者报告的残疾 (PDDS) 和MS性能测试 (MSPT) 的结果.
主要成果:
- 与24个月的不使用DMT组相比,接受干扰素β-1a治疗的患者 (老年人和年轻人) 的ARR率较低.
- 老年干扰素β-1a治疗的患者在患者确定的疾病阶段 (PDDS) 中的平均变化为-0.13 (1.08),而在没有DMT的老年患者中为0.20 (1.30).
- 在接受干扰素治疗的老年患者中,残疾进展稳定.
结论:
- 干扰素β-1a治疗与老年多发性硬化症患者 (≥60岁) 的持续低复发率有关.
- 在接受干扰素β-1a治疗的老年患者中,残疾进展在24个月内保持稳定.
- 这些发现支持使用干扰素β-1a在老龄化人口中治疗多发性硬化.
更多相关视频
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
12.1K
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
13.5K
相关概念视频
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
